The FDA has accepted the new drug application for the antipsychotic Bysanti and set a goal date for February 21, 2026.

Alkermes has a huge opportunity to expand its label to include pediatric patients with Schizophrenia and bipolar I disorder.

Older adults face unique mental health barriers, from misdiagnosis to stigma. This blog explores how we can improve care ...

If phase 3 trials of MM120 (lysergide d-tartrate) for anxiety and depression are successful, could the LSD-based drug become ...

Consider routine follow-up, especially after medication has been stopped Gabapentinoids, including gabapentin and pregabalin, are a class of drugs that have anticonvulsant, analgesic, and anxiolytic ...

Brittany Cartwright is defending her "honesty" about her apparently lackluster sex life with her estranged husband, Jax ...

Brittany Cartwright is sharing insight into Jax Taylor's abilities in the bedroom on Watch What Happens Live with Andy Cohen, ...

Compared with placebo, xanomeline/trospium as an add-on to atypical antipsychotics has not reached the threshold for a ...

With bipolar disorder, impulsivity can hijack decision ... According to the UPPS Impulsive Behavior Scale, impulsivity includes four main components: There’s virtually no limit to the risky ...

A pioneering Nova Scotia program that provides patients with basic psychiatric diagnoses is winning praise for slashing wait ...

BMS has reported topline outcomes from the ARISE trial of Cobenfy as an adjunctive treatment to atypical antipsychotics for schizophrenia.